Monopar Therapeutics Stock Today
| MNPR Stock | USD 44.74 5.64 14.42% |
PerformanceGood
| Odds Of DistressLow
|
Monopar Therapeutics is selling at 44.74 as of the 21st of March 2025; that is 14.42 percent increase since the beginning of the trading day. The stock's lowest day price was 39.1. Monopar Therapeutics has only a 8 % chance of going through financial distress over the next few years and had a good performance during the last 90 days. The performance scores are derived for the period starting the 21st of December 2024 and ending today, the 21st of March 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 19th of December 2019 | Category Healthcare | Classification Health Care |
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company was incorporated in 2014 and is headquartered in Wilmette, Illinois. Monopar Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 6.1 M outstanding shares of which 32.52 K shares are now shorted by private and institutional investors with about 0.81 trading days to cover. More on Monopar Therapeutics
Moving together with Monopar Stock
Moving against Monopar Stock
Monopar Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| Thematic Idea | Pharmaceutical Products (View all Themes) | |||||||||||||||||||||||||||||||||||
| Old Name | Minrav Projects Ltd | |||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Pharmaceutical Products, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||
Debt LevelsMonopar Therapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Monopar Therapeutics' financial leverage. It provides some insight into what part of Monopar Therapeutics' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||
Monopar Therapeutics (MNPR) is traded on NASDAQ Exchange in USA. It is located in 1000 Skokie Boulevard, Wilmette, IL, United States, 60091 and employs 9 people. Monopar Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 273.03 M. Monopar Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 6.1 M outstanding shares of which 32.52 K shares are now shorted by private and institutional investors with about 0.81 trading days to cover.
Monopar Therapeutics currently holds about 16.46 M in cash with (7.86 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.29.
Check Monopar Therapeutics Probability Of Bankruptcy
Ownership AllocationThe market capitalization of Monopar Therapeutics is $273.03 Million. Monopar Therapeutics holds significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.
Check Monopar Ownership Details
Monopar Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Jpmorgan Chase & Co | 2024-12-31 | 2 K | |
| Tower Research Capital Llc | 2024-12-31 | 696 | |
| Goss Wealth Management Llc | 2024-12-31 | 600 | |
| Wells Fargo & Co | 2024-12-31 | 250 | |
| Sbi Securities Co Ltd | 2024-12-31 | 100.0 | |
| Bank Of America Corp | 2024-12-31 | 28.0 | |
| Federation Des Caisses Desjardins Du Quebec | 2024-12-31 | 16.0 | |
| Gerber Llc | 2024-09-30 | 0.0 | |
| Northern Trust Investments N A | 2024-12-31 | 0.0 | |
| Hhg Plc | 2024-12-31 | 1 M | |
| Adage Capital Partners Gp Llc | 2024-12-31 | 599.2 K |
Monopar Therapeutics Historical Income Statement
Monopar Stock Against Markets
Monopar Therapeutics Corporate Executives
Elected by the shareholders, the Monopar Therapeutics' board of directors comprises two types of representatives: Monopar Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Monopar. The board's role is to monitor Monopar Therapeutics' management team and ensure that shareholders' interests are well served. Monopar Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Monopar Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Christopher Starr | CoFounder Board | Profile | |
| Quan Vu | Principal CFO | Profile | |
| Kim CPA | Secretary, CFO | Profile | |
| Karthik CFA | Principal CFO | Profile |
Additional Tools for Monopar Stock Analysis
When running Monopar Therapeutics' price analysis, check to measure Monopar Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Monopar Therapeutics is operating at the current time. Most of Monopar Therapeutics' value examination focuses on studying past and present price action to predict the probability of Monopar Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Monopar Therapeutics' price. Additionally, you may evaluate how the addition of Monopar Therapeutics to your portfolios can decrease your overall portfolio volatility.